|
Market Cap (19-May) $4,758,880 (1,313th) |
Close (30-Jun) $1.51 |
Volume (30-Jun) 12,937 |
Shortsold (8-Aug) 2,108 (0.02%) (508th) |
|
52w High $1.09 |
52w Low $0.280 |
P/E - |
EPS -0.42 |
ZLD released this announcement to the ASX on 17 February 2023, 9:32. The announcement is marked as price sensitive, and is 3 page(s) in length and 281.75kb in size.
You can view all announcements from ZLD and see how they appear on a price chart on the announcements page.
At the date of this announcement, ZLD was 0.031% short sold according to ASIC data. It was ranked the 485th most shorted stock on the ASX. It remains ranked 508th as of the latest reported data (08 August 2024).
| Other Recent Announcements from ZLD | |
|---|---|
| Amendment to ASX announcement - Zelira's diabetic nerve pai | 8 June 2023, 9:47 |
| Initial Director's Interest Notice | 1 June 2023, 15:29 |
| Final Director's Interest Notice | 1 June 2023, 15:27 |
| Trading Halt | 17 February 2023, 9:32 |
| ZLD secures US$8.6 million funding for HOPE 1 US FDA trials | 15 February 2023, 9:42 |
| Trading Halt | 13 February 2023, 9:25 |
| Appendix 4C Cash Flow Report | 31 January 2023, 8:36 |
You must be logged in to post a reply.
Zelira Therapeutics 